ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

The lead drug (Nuplazid) is enjoying aggressive sales growth and thereby trumping competitors. In taking success to the next level, Acadia is expanding Nuplazid's label for schizophrenia and Alzheimer's psychosis.

Acadia: Catalysts Stacking

ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro Announces $4 Million Add'l Investment by Digital Power Lending Upon Completion of Phase 1 Clinical Trial for Treatment for Alzheimer's

Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

LAS VEGAS--(BUSINESS WIRE)---- $ACAD #ACImmune--BitNile Holdings Announces Add'l Investment in Alzamend from Completion of Phase 1 First-in-Human Clinical Trial for Lithium Treatment of Alzheimer's

BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 4, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067

Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022

Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.

Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg once daily, ACP-044 400 mg four times daily and placebo treatment arms, was not met. A trend favoring the ACP-044

Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain

ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro Contracts with Altasciences & iResearch Atlanta to Manage & Conduct Its Phase IIA Multiple Ascending Does Study in Alzheimer's Patients

Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer's

ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Why Is Acadia (ACAD) Up 1% Since Last Earnings Report?

ATLANTA--(BUSINESS WIRE)---- $ACAD #ACAD--Alzamend Neuro Announces Full Data Set from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia-Related to Alzheimer's

Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking oral presentation on the efficacy and safety data from the Phase 3 Lavender study of trofinetide, an investigational treatment for Rett syndrome (RTT), will be presented at the 2022 American Academy of Neurology Annual Meeting (AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022. “We look forward to the upcoming presentation of the Phase 3 Lavender results at this year's AAN

Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 1st Annual Needham Virtual Neuroscience Forum on Wednesday, March 16, 2022 at 3:20 p.m. Eastern Time. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through April 16, 2022. About Acadia Pharmaceuticals Acadia is advancing breakthroughs i

Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022

Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.

Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Administration (FDA) for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The FDA's Division of Psychiatry has also advised the company that it is planning to hold an Advisory Committee meeting in

Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through April 9, 2022. About Acadia Pharmaceuticals Aca

Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.

Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript

Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021. “Acadia delivered strong fourth quarter and full year results with an increase in net sales of 10 percent year-over-year, driven by growth in both NUPLAZID prescriptions and market share,” said Steve Davis, Chief Executive Officer. “We recently resubmitted our sNDA for pimavanserin for Alzheimer's disease psychosis to the FDA. In

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Emergent BioSolutions

While the theme underperformed considerably in 2021, declining by 31%, it has gained about 2% year-to-date in 2022, outperforming the S&P 500, which remains down by about 9%.

These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022?

Acadia's NUPLAZID has proven itself as a significant contributor in treatment of Parkinson's disease psychosis. Acadia focused its sNDA on Alzheimer's disease psychosis in response to its CRL for NUPLAZID in treatment of dementia-related psychosis.

Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right

Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) to the U.S. Food and Drug Administration (FDA). This resubmission is in response to the FDA's April 2, 2021 Complete Response Letter (CRL) to the sNDA originally submitted for a proposed indication for pimavanserin for the t

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer's Disease Psychosis

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 28, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or

News for ACADIA Pharma Stock (ACAD)